

Effects of medical drugs according to sweating localization in primary hyperhidrosis

BAYRAKÇI Onur

Ersin Arslan Training and Research Hospital, Thoracic Surgery Department, Turkey

ABSTRACT

Background:Primary hyperhidrosis is excessive sweating localized to different parts of the body, mostly on the hands. It is exact cause unknown, negatively affects the psychosocial structure of the person and a clinically important health problem.

Aims:In the study, it was aimed to examine the effects of drugs used on primary hyperhidrosis.

Study Design:The drugs used by the patients who applied to the thoracic surgery clinic with the complaint of sweating and their effects were analyzed retrospectively. Ersin Arslan Training and Research Hospital Thoracic Surgery Clinic between January 1, 2015, and September 30, 2021 (outcomes of seven years).

Methodology:A total of 120 patients(45 female, 75 male and age range 8-67) with sweating complaints were identified. Age, gender, sweating localization and drugs used were examined. Statistically, data were analyzed with 95% confidence interval(CI) and Chi Square test.

Results:A total of 120 patients were analyzed. 37.5% were female and 62.5% male.The mean age was 27.1 ± 1.54 years.Patients were use 23.4% Aluminum hydrochloride cream),20.8% Bornaprine hydrochloride, 20% Hyoscine-N-butylbromide.According to sweating localizations;42.6% palmar only, 18.7% palmar and axilla, 18.7% palmar and craniofacial, 7.8% palmar and plantar, 5.9% diffuse, 4.5% cranial, 1.8% palmar and abdomen.It is more often between ages of 21-30 and in male.According to the complaints of patients with a history of using medical treatment; there were 34.5% partial response and 20.2% complete response, and no response to medical treatment in 45.3%.

Conclusion:In the study; according to the localization of sweating;Aluminum hydrochloride cream reduces sweating on the palmar, and Hyoscine-N-butylbromide reduces axillary and palmar sweating. Bornaprine hydrochloride reduces sweating on all localizations except craniofacial and abdomen, and is related with a complete response on palmar sweating.According to sweating localizations; although there are localizations where all three drugs used are effective, it has been concluded that these drugs used in primary hyperhidrosis do not respond fully at a high rate.

Keywords: drugs, hyperhidrosis, medical, sweating, treatment

1.INTRODUCTION

Primary hyperhidrosis is excessive sweating localized to different parts of the body, mostly on the hands. This disease, the exact cause of which is unknown, negatively affects the psychosocial structure of the person. The incidence in and adolescents children under the age of 18 has been reported to be 1.6% [1]. Sweating is one of the body's temperature regulation mechanisms. Humans have eccrine, apocrine, and apoeccrine sweat glands. Apocrine and apoeccrine glands are located in the axilla. Eccrine glands are localized in much parts of the body, especially in the palmar and plantar parts [2]. Although there is sweating on the axilla, the primary hyperhidrosis of cause is generally thought to be activation of the eccrine glands. This activation occurs as a result of sympathetic stimulation on normal eccrine sweat glands [3]. Primary hyperhidrosis, causes psychosocial and dermatological problems in humans, is an important health problem.

2. MATERIAL AND METHODS

Patients who admitted to the thoracic surgery outpatient clinic with the complaint of sweating between January 1, 2015, and September 30, 2021 were analyzed retrospectively. A total of 120 patients (45 female, 75 male and age range 8-67) with sweating complaints were identified. Age, gender, sweating

localization and drugs used were examined. Statistically, data were analyzed with 95% confidence interval (CI) and Chi Square test.

3. RESULTS AND DISCUSSION

A total of 120 patients were analyzed. 37.5% were female and 62.5% male (95%CI ± 0.08). The mean age was 27.1 years (± 1.54). It was determined that 6.7% of the patients hyperthyroidism, 12.5% of them antidepressant use and 29.2% increase with stress. According to sweating localizations; 42.6% palmar only, 18.7% palmar and axilla, 18.7% palmar and craniofacial, 7.8% palmar and plantar, 5.9% diffuse, 4.5% cranial, 1.8% palmar and abdomen. Patients were use 23.4% Aluminum hydrochloride cream (3-4 times a day), 20.8% Bornaprine hydrochloride (4 mg/day), 20% Hyoscine-N-butylbromide (2x10 mg/day), 5.8% antithyroid drug for sweating. The complaint of sweating was evaluated according to whether the response was received in the first month after the drug use. (Figure 1 and 2).

Figure 1. Distribution of age and gender





Figure 2. Localization of sweating



Complete response indicates that there is no sweating complaint, and partial response is decrease of complaint but continue in first month. According to the complaints of patients with a history of using medical treatment; there were 34.5% partial response and 20.2% complete response, and no response to medical treatment in 45.3%.

In the study, primary hyperhidrosis is more than in men and between the ages of 21 and 30 ($p < 0.0001$). Palmar sweating was more than in male ($p < 0.02$) and palmar and craniofacial sweating in female ($p < 0.03$). 14.1% complete response, 24.1% partial response to medical treatments, and 31.6% didn't respond to treatment ($p < 0.001$). Localized sweating is most often on the palmar only. Partial response to treatment and no response, were related with Aluminum hydrochloride, Hyoscine-N-butylbromide and Bornaprine hydrochloride ($p < 0.0002$). Complete response was related with Bornaprine hydrochloride ($p < 0.0004$). Treatment of Aluminum hydrochloride was related partial response to palmar sweating ($p < 0.004$), and that no response to diffuse sweating and palmar and abdomen ($p < 0.0001$). Hyoscine-N-butylbromide treatment partially responded to sweating of the

palmar and axillae ($p<0.04$), but didn't respond to diffuse with palmar and abdomen ($p<0.0001$). Bornaprine hydrochloride treatment was a partial response to sweats other than craniofacial, palmar and craniofacial, palmar and abdomen ($p<0.0001$). Antidepressant use and stress were **related** with primary hyperhidrosis ($p<0.05$) (Table 1).

Table 1. Statistical analysis of drugs

Localization	p<	No Response		Partial Response			Complete Response		
		ODSS	D	p<	ODSS	D	p<	ODSS	D
Palmar	0.05	2.141		0.004	0.642	AH	0.0001	1.240	BH
Palmar and axilla	0.02	0.773		0.04	2.700	HNB			
Palmar and Craniofacial	0.02	0.773	BH	0.2					
Palmar and Plantar	0.0001	0.595		0.07	0.774	BH			
Cranial	0.1			0.0001	2.173	BH			
Palmar and Abdomen	0.0001	2.189	AH, HNB, BH	0.4					
Craniofacial	0.3		BH	0.4					
Diffuse	0.0001	0.856	AH, HNB	0.0001	2.510	BH			

*D:Drugs AH: Aluminum hydrochloride HNB: Hyoscine-N-butylbromide BH: Bornaprine hydrochloride

*Statistical analysis: Chi square test

Aluminum hydrochloride (AH) is among the most commonly used topical in the treatment of sweating [4]. Hyoscine-N-butylbromide (HNB) is an antiparasymphathetic substance that blocks acetylcholine on smooth muscle and glands [5]. For this reason, it is preferred in the treatment of sweating in order to affect glands with parasympathetic innervation. Bornaprine hydrochloride (BH) is an anticholinergic substance that is also used in the treatment of neurological diseases. Drugs is preferred in the treatment of hyperhidrosis due to its inhibition of the innervation of the glands. In retrospective study, the effects of these drugs were examined. It was determined that there was no effect of all three drugs in the case of palmar and abdominal sweating together. Diffuse sweating is usually associated with hyperthyroidism and cause of secondary hyperhidrosis. Therefore, the effects of antithyroid drugs were not included in the study. However, although AH and HNB had no effect on diffuse sweating, it was found that BN partially decreased sweating. Although BN reduces sweating in localized cranial sweating, it has no effect on sweating with craniofacial components. It was found that AH reduced palmar sweating, HNB reduced axillary and palmar sweating. According to its localization, it was found that the complete response was with the effect of BH on palmar sweating. In patients who do not respond to medical treatments; thoracic sympathectomy is preferred surgically, especially in palmar hyperhidrosis [6].

4. CONCLUSION

In the study; according to the localization of sweating; AH reduces sweating on the palmar, HNB axillary and palmar sweating. BH reduces sweating on all localizations except craniofacial and abdomen, and is **related** with a complete response on palmar sweating. According to sweating localizations; although there are localizations where all three drugs used are effective, it has been concluded that these drugs used in primary hyperhidrosis do not respond fully at a high rate.

COMPETING INTERESTS

All authors declared that there is no conflict of interest.

FUNDING

No financial support has been received

ETHICAL APPROVAL

Republic of Turkey Ministry of Health 2021-09-18T23_48_37 numbered and Gaziantep University Medical Ethics Committee 2021/323 numbered approval have been received.

Consent Disclaimer:

As per international standard or university standard, patient's consent has been collected and preserved by the authors.

REFERENCES

1. Strutton DR, Kowalski JW, Glaser DA, et al. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: Results from a national survey. *J Am Acad Dermatol* 2004; 51:241-248.
2. Lonsdale-Eccles A, Leonard N, Lawrence C. Axillary hyperhidrosis: Eccrine or apocrine? *Clin Exp Dermatol* 2003;28:2-7.
3. Romero FR, Haddad GR, Miot HA, et al. Palmar hyperhidrosis: clinical, pathophysiological, diagnostic and therapeutic aspects. *An Bras Dermatol*. 2016;91:716–725.
4. Hashmonai M, Kopelman D, Assalia A. The treatment of primary palmar hyperhidrosis: A review. *Surg. Today*. 2000;30.
5. Leslie AS. Pharmacotherapy Update: Hyoscine Butylbromide in the Treatment of Abdominal Spasms. *Clinical Medicine. Therapeutics* 2009;1:647-655.
6. Moran KT, Brady MP. Surgical management of primary hyperhidrosis. *Br J Surg*. 1991;78(3):279-83.